French vaccines start-up Osivax was spun off from Imaxio SA in 2017 from which the company obtained its oligoDOM pro-immunogenic antigen re-engineering technology. The spin-off’s CEO Alexandre Le Vert told Scrip it plans to bring about a paradigm shift in the prevention of seasonal and pandemic influenza, and potentially develop a universal flu vaccine from its technology.
He said Osivax’s technology platform was 12 years in the making and provides a versatile basis to trigger effective immune...
Welcome to Scrip
Create an account to read this article
Already a subscriber?